SAN FRANCISCO – Abbvie Inc.'s chief financial officer, Bill Chase, said competition for market share and the pricing saga playing out between its new hepatitis C virus (HCV) therapy, Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) and Gilead Sciences Inc.'s Harvoni (sofosbuvir/ledipasvir) is "exactly what we expected," but that the media's focus on price has been much heavier than merited.